Lisa Dreyer - Pappas Capital

Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG

SAN CARLOS, Calif.--April 16, 2025--Glycomine, Inc., a biotechnology company focused on developing transformative new therapies for orphan diseases, today announced a $115 million Series C financing to advance its lead candidate, GLM101, into a Phase 2b clinical trial. The financing was led by CTI Life Sciences Fund, funds managed by abrdn Inc., and Advent Life Sciences, alongside continued investment from existing investors, Novo Holdings, Sanofi Ventures, Abingworth, RiverVest Venture Partners, Sanderling Ventures, Chiesi Ventures, Remiges Ventures, and Asahi Kasei Ventures.

Glycomine - 04/16/2025

Solu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial

BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series A financing that included participation from five new investors – Eli Lilly and Company, Biovision Ventures, Pappas Capital, Hengdian Group Capital (HgC), and The Leukemia & Lymphoma Society Therapy Acceleration Program® – as well as continued support from existing Solu investors Longwood Fund, DCVC Bio, Santé Ventures, Astellas Venture Management, and Alexandria Venture Investments. The company also announced initiation of treatment of the first patient in its first-in-human Phase 1 clinical trial evaluating STX-0712 in patients with resistant/refractory chronic myelomonocytic leukemia (CMML) and other hematologic malignancies.

0-Homepage Feature / 0-Megaphone / Solu Therapeutics - 04/10/2025

Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett syndrome (TREE study)

Barcelona, Spain – 4 March 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces that the first patient in the TREE study has been dosed with leriglitazone. TREE is a phase 2a clinical study assessing the safety and efficacy of lead candidate leriglitazone, a novel, brain-penetrant and selective PPAR gamma agonist, to treat patients with Rett syndrome.

Minoryx - 03/07/2025

Tune Therapeutics Names John McHutchison as CEO and Chairman of the Board

DURHAM, N.C. & SEATTLE--March 4, 2025--Leading epigenome company Tune Therapeutics is proud to announce that veteran drug-development executive John McHutchison AO, MD will be its new CEO and Chairman of the Board. Dr. McHutchison is an internationally recognized leader of the biopharma industry and accomplished drug developer who brings decades of executive leadership and experience in developing novel therapeutics.

Tune Therapeutics - 03/04/2025

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer

BOSTON, March 03, 2025 -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that additional Phase 1 data evaluating bel-sar (AU-011) for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) will be presented at the 40^th Annual European Association of Urology (EAU) Congress being held March 21-24, 2025, in Madrid, Spain. Aura will also participate in the EAU Research Forum during the Congress.

Aura - 03/03/2025

CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial

SAN CARLOS, Calif.--February 20, 2025--CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid onset, small molecule drugs to treat psychiatric and neurodegenerative diseases, announced today that it has treated its first subject with CuraAX, an alpha-1A adrenoceptor agonist, in a Phase 1 clinical trial. The company is developing CuraAX for patients with neurogenic orthostatic hypotension (nOH). Neurogenic orthostatic hypotension is a condition characterized by a significant, sudden drop in blood pressure upon standing, resulting in debilitating dizziness, fainting and cognitive impairment, due to inadequate blood flow to the brain. CuraAX is also expected to benefit cognition in patients with a range of neurologic conditions.

CuraSen Therapeutcis - 02/20/2025

Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs

DURHAM, N.C. & SEATTLE--January 12, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation. The funding will accelerate the development of the company’s existing pipeline, currently anchored by Tune-401 – its clinical-stage epigenetic silencing drug for chronic Hepatitis B (HBV). It will also support the development of additional gene, cell, and regenerative therapy programs already underway at Tune, and to progress its broader mission of bringing the power and versatility of epigenetic therapies to bear on common and chronic diseases.

Tune Therapeutics - 01/13/2025

Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis

SALT LAKE CITY--(December 19, 2024)--Sorriso Pharmaceuticals, a biopharmaceutical company developing novel orally dosed antibodies for immune-mediated disease, today announced positive results from its Phase 1b clinical trial evaluating SOR102, an oral, dual-acting biologic targeting TNFα and IL-23, in patients with ulcerative colitis (UC). The study met its primary objectives, demonstrating a favorable safety and tolerability profile. Additionally, key exploratory efficacy endpoints showed promising activity of SOR102 across multiple clinical endpoints. This is the first successful demonstration of an orally dosed antibody delivering clinical efficacy.

Sorriso Pharmaceuticals - 12/19/2024

Minoryx's leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy

Barcelona, Spain and Düsseldorf, Germany – 11 December 2024 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of CNS disorders, today announced that the NEXUS trial has been completed and that the primary endpoint has been met. The parties intend to file for European Marketing Authorization of leriglitazone in pediatric and adult cerebral Adrenoleukodystrophy (cALD) patients by mid-2025.

Minoryx - 12/11/2024

EarthOptics Secures $24 Million in Financing to Drive Expansion and Revolutionize Soil Digitization

ARLINGTON, Va., Nov. 19, 2024 -- EarthOptics, the industry leader in soil digitization and Predictive Agronomy, has announced the successful completion of $24 million in financing. This capital raise includes new partners Cibus Capital, RuralWorks Partners and Norinchukin Bank and is led by current investors Conti Ventures and The Production Board, with notable participation from Leaps by Bayer, S2G Ventures, Middleland Capital’s VTC Ventures, Cooperative Ventures, iSelect Fund, Serra Ventures, TO VC, Route 66 Ventures, Shell Ventures, Pappas Capital, CNH Ventures, and Rabo Ventures.

This investment underscores EarthOptics' unwavering commitment to advancing soil intelligence and enabling farmers, ranchers, and their advisors to make data-driven decisions that maximize profitability and sustainability. The funds will be deployed to accelerate technological innovation, broaden the company's geographic reach, and solidify its position as the authoritative source for soil insights.

EarthOptics - 11/19/2024

Investor Login

Solu Therapeutics Closes $41M Series A…